Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
News|Articles|September 14, 2026
Consistency as a Competitive Advantage in a Changing Market
Author(s)CoverMyMeds
This infographic leverages IQVIA data and analytics to explore how one pharmaceutical brand used CoverMyMeds’ prior authorization strategies to achieve an observed average 22 percentage point improvement in claim approval rates—growing and defending market share in a highly managed class.
Related to this article
The interleukin-6 receptor inhibitor gains a second indication, though one of two phase 3 trials missed its primary endpoint.
European regulators are increasing pressure on clinical trial sponsors to report study results on time, rolling out new monitoring, reminders and guidance as patient advocates welcome the progress but question whether stronger oversight and enforcement will follow.
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.
Fox Rothschild's Mark Wagner on why drug shortages are so hard to fix — from the definition gap to API dependency to three-year site approvals.
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
AstraZeneca will pay insitro $40 million upfront to apply AI to target discovery in MASH and cardiomyopathies, with no candidates named yet.
AI does not end uncertainty in pharma strategy. Its value depends on how well leaders blend it with experience and evidence while keeping judgment human.
Trending on PharmExec
1
FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease
2
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
3
EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe
4
The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble
5